{"title": "Support References", "author": null, "url": null, "hostname": null, "description": "TVAX Biomedical, Inc. is a biotechnology company currently performing phase II clinical trials to test a unique natural cancer immunotherapy as a treatment for brain cancer.", "sitename": null, "date": "1997-01-01", "cleaned_text": "References Support References [Adoptive cell therapy for the treatment of patients with metastatic melanoma.](http://www.ncbi.nlm.nih.gov/pubmed?term=Rosenberg%20SA,%20Dudley%20ME,%20Curr%20Opin%20Immunol.%202009%20Apr;21%282%29%3A233-40.%20Epub%202009) Rosenberg SA, Dudley ME, Curr Opin Immunol. 2009 Apr;21(2):233-40. Epub 2009 Mar 21 [Adoptive cell therapy for patients metastatic melanoma: evaluation of intensive myeloablative chemoradiation 16:919-43 (2007) [Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim.](http://www.ncbi.nlm.nih.gov/pubmed?term=Wiseman%20CL,%20Kharazi%20A.%20Breast%20J.%2012%3A475-80%20%282006%29) Wiseman CL, Breast J. hapten-modified vaccine for human cancer.](http://www.ncbi.nlm.nih.gov/pubmed?term=Berd%20D.%20Expert%20Rev%20Vaccines.%203%3A521-7%20%282004%29) Berd D. Rev Vaccines. 3:521-7 (2004) [Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed?term=Schwaab%20T%2C%20et%20al.%2C%20J%20Urol.%20171%3A1036-42%20%282004%29) Schwaab T, et al., J Urol. 171:1036-42 (2004) [Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.](http://www.ncbi.nlm.nih.gov/pubmed?term=Jocham%20D%2C%20et%20al.%2C%20Lancet.%20363%3A594-599%20%282004%29) Jocham D, 363:594-599 autologous tumor vaccines al., J Natl Cancer Inst. 96:326-331 II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.](http://www.ncbi.nlm.nih.gov/pubmed?term=Chang%20AE%2C%20et%20al.%2C%20J%20Clin%20Oncol%2021%3A884-90%20%282003%29) Chang AE, et al., J Clin Oncol 21:884-90 (2003) [Vaccination with irradiated autologous to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with (2003) [Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer lymphocytes.](http://www.ncbi.nlm.nih.gov/pubmed/16817692) Sloan AE, Neurosurg Focus. 2000 Dec 15;9(6):e9. [A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade FP, et al., [Cancer engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.](http://www.ncbi.nlm.nih.gov/pubmed?term=Nelson%20DS%2C%20et%20al.%2C%20Cancer%20Chemother%20Pharmacol.%2046%20Suppl%3AS67-72%20%282000%29) Nelson DS, et al., Cancer Chemother Pharmacol. 46 Suppl:S67-72 (2000) [Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.](http://www.ncbi.nlm.nih.gov/pubmed?term=Simons%20JW%2C%20et%20al.%2C%20Cancer%20Res.59%3A5160-8%20%281999%29) Simons JW, et al., Cancer Res.59:5160-8 (1999) [Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.](http://www.ncbi.nlm.nih.gov/pubmed?term=Vermorken%20JB%2C%20et%20al.%20Lancet.%20353%3A345-50%20%281999%29) Vermorken JB, et al. Lancet. 353:345-50 vaccine as a treatment for human Berd D, et al., Semin Oncol. 25:646-53 (1998) [Vaccination autologous melanoma cells to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients melanoma.](http://www.ncbi.nlm.nih.gov/pubmed?term=Soiffer%20R%2C%20et%20al.%2C%20Proc%20Natl%20Acad%20Sci%20USA.%2095%3A13141-6%20%281998%29) Soiffer R, 95:13141-6 (1998) [Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.](http://www.ncbi.nlm.nih.gov/pubmed?term=Simons%20JW%2C%20et%20al.%2C%20Cancer%20Res.%2057%3A1537-46%20%281997%29) Simons JW, et Res. 57:1537-46 (1997) [Adoptive transfer of anti-CD3-activated CD4+ T cells and liposome-encapsulated interleukin-2 and 3LL tumors establish al., Blood. 89:2529-2536 (1997) [Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.](http://www.ncbi.nlm.nih.gov/pubmed?term=Chang%20AE%2C%20et%20al.%2C%20J%20Clin%20Oncol.%2015%3A796-807%20%281997%29) Chang AE, et al., J Clin Oncol. 15:796-807 (1997) [A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor.](http://www.ncbi.nlm.nih.gov/pubmed?term=Dranoff%20G%2C%20et%20al.%2C%20Hum%20Gene%20Ther.%208%3A111-23%20%281997%29) Dranoff G, et al., Hum Gene Ther. 8:111-23 (1997) [Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.](http://www.ncbi.nlm.nih.gov/pubmed?term=Holladay%20FP%2C%20et%20al.%2C%20J%20Neurooncol.%2027%3A179-89%20%281996%29) Holladay FP, et I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed?term=Berns%20AJ%20et%20al.%2C%20Hum%20Gene%20Ther.%206%3A347-68%20%281995%29) Berns AJ et al., Hum Gene Ther. 6:347-68 (1995) [Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage factor stimulates potent, cells an autologous tumor cell: USA. 44:1671-6 (1984) [High-dose Chemotherapy and Adoptive Immunotherapy in the Treatment of Recurrent Pediatric Brain Tumors](http://tvaxbiomedical.com/documents/High-dose-Chemotherapy-and-Adoptive-Immunotherapy.pdf). Peres E, et al. E. Neuropediatrics. 39:151-6 (2008) "}